Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 12 (December)

1. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
   Clin Cancer Res, 13(23): 7029-36. [Abstract] [Full-text]
2. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.
   Oncologist, 12(11): 1288-98. [Abstract] [Full-text]
3. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast.
   Oncologist, 12(11): 1276-87. [Abstract] [Full-text]
4. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer.
   Int J Gynecol Cancer. [Abstract] [Full-text]
5. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
   Expert Rev Anticancer Ther, 7(12): 1763-71. [Abstract] [Full-text]
6. Herceptin.
   Handb Exp Pharmacol. [Abstract] [Full-text]
7. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
   Cancer Chemother Pharmacol, 61(3): 509-14. [Abstract] [Full-text]
8. Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.
   Ann Oncol, 18(12): 1963-8. [Abstract] [Full-text]
9. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination.
   Ann Oncol, 18(12): 1969-75. [Abstract] [Full-text]
10. FoxA1 as a lineage-specific oncogene in luminal type breast cancer.
    Biochem Biophys Res Commun, 365(4): 711-7. [Abstract] [Full-text]
11. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Cancer Res, 67(24): 11991-9. [Abstract] [Full-text]
12. In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches.
    Mol Cancer Ther, 6(12): 3091-100. [Abstract] [Full-text]
13. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
    J Clin Pathol, 61(1): 89-94. [Abstract] [Full-text]
14. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
    Cancer, 112(1): 17-26. [Abstract] [Full-text]
15. Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.
    Exp Biol Med (Maywood), 233(1): 76-83. [Abstract] [Full-text]
16. Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium.
    Health Policy. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.